Nitric Oxide Synthase II Repels Metastasis Despite Upregulated Angiogenesis

Strategic Insights -

Nitric oxide synthase II has been identified as a potential therapeutic agent for cancer treatment due to its ability to repel metastasis despite promoting angiogenesis. Researchers at the University of Texas MD Anderson Cancer Center have developed a gene therapy approach using adenoviral vectors to deliver the NOS II gene into human tumors. The resulting production of nitric oxide significantly upregulated multiple angiogenic molecules, yet surprisingly, the tumor cells did not form tumors or metastases in ectopic or orthotopic xenograft nude mouse models. This dramatic loss of malignancy was attributed to NO-mediated apoptosis. The study demonstrates a dose-dependent antitumor activity of NO in vitro and in vivo, regardless of its upregulation of protumor factors.

Key Takeaways:

  • Adenoviral vectors were used to effectively transfer the NOS II gene into various human tumors, producing nitric oxide.
  • The production of NO significantly upregulated multiple angiogenic molecules, but did not promote tumor growth or metastasis in xenograft mouse models.
  • The antitumor activity of NO was demonstrated to be dose-dependent and effective in both in vitro and in vivo settings.
  • NO-mediated apoptosis was identified as the primary mechanism behind the dramatic loss of malignancy.
  • Researchers generated adenoviral vectors harboring mutant NOS II genes with defined levels of enzymatic activity, which directly correlated with antitumor activity.
  • The study highlights the potential of nitric oxide synthase II as a therapeutic agent for cancer treatment.

Statistics:

  • 102: The volume number of the journal Proceedings of the National Academy of Sciences of the United States of America in which the study was published.
  • 24: The issue number of the journal in which the study was published.
  • 8758-8763: The page numbers of the journal article by Le and colleagues.
  • 1515 Holcombe Blvd.: The physical address of the University of Texas MD Anderson Cancer Center's Department of Gastrointestinal Medical Oncology.

Sources:

  • Le, X.D., et al. (2005). Nitric oxide synthase II suppresses the growth and metastasis of human cancer regardless of its up-regulation of protumor factors. Proc Natl Acad Sci USA, 102(24), 8758-8763.
  • University of Texas MD Anderson Cancer Center. (n.d.). Adenoviral Vector. Retrieved from [undefined link]
  • National Academy of Sciences. (n.d.). Proceedings of the National Academy of Sciences of the United States of America. Retrieved from [undefined link]
  • Health & Medicine Week editors. (2005). Nitric oxide synthase II repels metastasis despite upregulated angiogenesis. Health & Medicine Week, [undefined link]